Hyperoxia resensitizes chemoresistant glioblastoma cells to temozolomide through unfolded protein response

Anticancer Research

Volumn 34, Issue 6, 2014, Pages 2957-2966

  Lee, Derek ^a   Sun, Stella ^a   Ho, Amy S W ^a   Kiang, Karrie M Y ^a   Zhang, Xiao Qin ^a   Xu, Fei Fan ^a   Leung, Gilberto K K ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Chemoresistance; ER stress response; Glioblastoma; Hyperoxia; P4HB; Temozolomide

Indexed keywords

CHAPERONE; GLUCOSE REGULATED PROTEIN 78; POLYPEPTIDE; PROLYL 4 HYDROXLASE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE; P4HB PROTEIN, HUMAN; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEIN DISULFIDE ISOMERASE;

ARTICLE; AUTOPHOSPHORYLATION; CANCER RESISTANCE; CELL SURVIVAL; CELL VIABILITY; CHEMOSENSITIVITY; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIVITY; ENDOPLASMIC RETICULUM STRESS; GENE OVEREXPRESSION; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; GLIOMA CELL; HUMAN; HUMAN CELL; HYPEROXIA; IC50; OXYGEN CONCENTRATION; OXYGENATION; PROTEIN FOLDING; UNFOLDED PROTEIN RESPONSE; WESTERN BLOTTING; APOPTOSIS; BRAIN TUMOR; CELL PROLIFERATION; CHEMORESISTANCE; DRUG EFFECT; DRUG RESISTANCE; ER STRESS RESPONSE; METABOLISM; MULTIMODALITY CANCER THERAPY; P4HB; PATHOLOGY; PHYSIOLOGY; TUMOR CELL CULTURE;

CHEMORESISTANCE; ER STRESS RESPONSE; GLIOBLASTOMA; HYPEROXIA; P4HB; TEMOZOLOMIDE;

ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; ENDOPLASMIC RETICULUM STRESS; GLIOBLASTOMA; HUMANS; HYPEROXIA; PROCOLLAGEN-PROLINE DIOXYGENASE; PROTEIN DISULFIDE-ISOMERASES; TUMOR CELLS, CULTURED; UNFOLDED PROTEIN RESPONSE;

EID: 84906320762     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Argyriou AA, Antonacopoulou A, Iconomou G and Kalofonos HP: Treatment options for malignant gliomas, emphasizing towards new molecularly targeted therapies. Crit Rev Oncol Hematol 69(3): 199-210, 2009.
2. Stupp R, Reni M, Gatta G, Mazza E and Vecht C: Anaplastic astrocytoma in adults. Crit Rev Oncol Hematol 63(1): 72-80, 2007.
3. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, Sabel M, Steinbach JP, Heese O, Reifenberger G, Weller M and Schackert G: Long-term survival with glioblastoma multiforme. Brain 130(Pt 10): 2596-2606, 2007.
4. Castro MG and Lowenstein PR: Neuro-oncology: The long and winding road-gene therapy for glioma. Nat Rev Neurol 9(11): 609-610, 2013.
5. Norden AD and Wen PY: Glioma therapy in adults. Neurologist 12(6): 279-292, 2006.
6. Darefsky AS, King JT Jr. and Dubrow R: Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries. Cancer 118(8): 2163-2172, 2012.
7. Sun S, Lee D, Ho AS, Pu JK, Zhang XQ, Lee NP, Day PJ, Lui WM, Fung CF and Leung GK: Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways. Neuro Oncol 15(5): 562-577, 2013.
8. Taylor LP: Diagnosis, treatment, and prognosis of glioma: five new things. Neurology 75(18 Suppl 1): S28-32, 2010.
9. Murat A, Migliavacca E, Hussain SF, Heimberger AB, Desbaillets I, Hamou MF, Ruegg C, Stupp R, Delorenzi M and Hegi ME: Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia. PLoS One 4(6): e5947, 2009.
10. Bar EE, Lin A, Mahairaki V, Matsui W and Eberhart CG: Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am J Pathol 177(3): 1491-1502, 2010.
11. Pistollato F, Abbadi S, Rampazzo E, Persano L, Della Puppa A, Frasson C, Sarto E, Scienza R, D'Avella D and Basso G: Intra-tumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. Stem Cells 28(5): 851-862, 2010.
12. Granowitz EV, Tonomura N, Benson RM, Katz DM, Band V, Makari-Judson GP and Osborne BA: Hyperbaric oxygen inhibits benign and malignant human mammary epithelial cell proliferation. Anticancer Res 25(6B): 3833-3842, 2005.
13. Taniguchi A: Adenine phosphoribosyltransferase deficiency and its purine metabolism. Nihon Rinsho 66(4): 784-788, 2008.
14. Moen I, Tronstad KJ, Kolmannskog O, Salvesen GS, Reed RK and Stuhr LE: Hyperoxia increases the uptake of 5-fluorouracil in mammary tumors independently of changes in interstitial fluid pressure and tumor stroma. BMC Cancer 9: 446, 2009.
15. Petre PM, Baciewicz FA Jr., Tigan S and Spears JR: Hyperbaric oxygen as a chemotherapy adjuvant in the treatment of metastatic lung tumors in a rat model. J Thorac Cardiovasc Surg 125(1): 85-95; discussion 95, 2003.
16. Brown JM: Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther 1(5): 453-458, 2002.
17. Harris AL: Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2(1): 38-47, 2002.
18. De-Souza EA, Pimentel FS, Machado CM, Martins LS, da-Silva WS, Montero-Lomeli M and Masuda CA: The Unfolded Protein Response Has a Protective Role in Yeast Models of Classic Galactosemia. Dis Model Mech 7(1): 55-61, 2013.
19. Nakamura S, Takizawa H, Shimazawa M, Hashimoto Y, Sugitani S, Tsuruma K and Hara H: Mild endoplasmic reticulum stress promotes retinal neovascularization via induction of BiP/GRP78. PLoS One 8(3): e60517, 2013.
20. Sun S, Lee D, Lee NP, Pu JK, Wong ST, Lui WM, Fung CF and Leung GK: Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide. J Neurooncol 109(3): 467-475, 2012.
21. Sun S, Wong TS, Zhang XQ, Pu JK, Lee NP, Day PJ, Ng GK, Lui WM and Leung GK: Protein alterations associated with temozolomide resistance in subclones of human glioblastoma cell lines. J Neurooncol 107(1): 89-100, 2012.
22. Oyadomari S and Mori M: Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ 11(4): 381-389, 2004.
23. Fels DR and Koumenis C: The PERK/eIF2alpha/ATF4 module of the UPR in hypoxia resistance and tumor growth. Cancer Biol Ther 5(7): 723-728, 2006.
24. Hein M and Graver S: Tumor cell response to bevacizumab single agent therapy in vitro. Cancer Cell Int 13(1): 94, 2013.
25. Koumenis C: ER stress, hypoxia tolerance and tumor progression. Curr Mol Med 6(1): 55-69, 2006.
26. Vaupel P, Mayer A and Hockel M: Tumor hypoxia and malignant progression. Methods Enzymol 381: 335-354, 2004.
27. Hockel M and Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93(4): 266-276, 2001.
28. Raa A, Stansberg C, Steen VM, Bjerkvig R, Reed RK and Stuhr LE: Hyperoxia retards growth and induces apoptosis and loss of glands and blood vessels in DMBA-induced rat mammary tumors. BMC Cancer 7: 23, 2007.
29. Stuhr LE, Raa A, Oyan AM, Kalland KH, Sakariassen PO, Petersen K, Bjerkvig R and Reed RK: Hyperoxia retards growth and induces apoptosis, changes in vascular density and gene expression in transplanted gliomas in nude rats. J Neurooncol 85(2): 191-202, 2007.
30. Wek RC and Cavener DR: Translational control and the unfolded protein response. Antioxid Redox Signal 9(12): 2357-2371, 2007.
31. Boelens J, Lust S, Offner F, Bracke ME and Vanhoecke BW: Review. The endoplasmic reticulum: a target for new anticancer drugs. In Vivo 21(2): 215-226, 2007.
32. Goplen D, Wang J, Enger PO, Tysnes BB, Terzis AJ, Laerum OD and Bjerkvig R: Protein disulfide isomerase expression is related to the invasive properties of malignant glioma. Cancer Res 66(20): 9895-9902, 2006.
33. Haefliger S, Klebig C, Schaubitzer K, Schardt J, Timchenko N, Mueller BU and Pabst T: Protein disulfide isomerase blocks CEBPA translation and is up-regulated during the unfolded protein response in AML. Blood 117(22): 5931-5940, 2011.
34. Basso K, Margolin AA, Stolovitzky G, Klein U, Dalla-Favera R and Califano A: Reverse engineering of regulatory networks in human B cells. Nat Genet 37(4): 382-390, 2005.
35. Lovat PE, Corazzari M, Armstrong JL, Martin S, Pagliarini V, Hill D, Brown AM, Piacentini M, Birch-Machin MA and Redfern CP: Increasing melanoma cell death using inhibitors of protein disulfide isomerases to abrogate survival responses to endoplasmic reticulum stress. Cancer Res 68(13): 5363-5369, 2008.
36. Talantov D, Mazumder A, Yu JX, Briggs T, Jiang Y, Backus J, Atkins D and Wang Y: Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res 11(20): 7234-7242, 2005.
37. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, Lizyness ML, Kuick R, Hayasaka S, Taylor JM, Iannettoni MD, Orringer MB and Hanash S: Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8(8): 816-824, 2002.
38. Xu S, Butkevich AN, Yamada R, Zhou Y, Debnath B, Duncan R, Zandi E, Petasis NA and Neamati N: Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase for ovarian cancer treatment. Proc Natl Acad Sci USA 109(40): 16348-16353, 2012.
39. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, Frierson HF Jr. and Hampton GM: Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 61(16): 5974-5978, 2001.
40. Healy SJ, Gorman AM, Mousavi-Shafaei P, Gupta S and Samali A: Targeting the endoplasmic reticulum-stress response as an anticancer strategy. Eur J Pharmacol 625(1-3): 234-246, 2009.
41. Xu C, Bailly-Maitre B and Reed JC: Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest 115(10): 2656-2664, 2005.
42. Jain K, Suryakumar G, Prasad R and Ganju L: Differential activation of myocardial ER stress response: A possible role in hypoxic tolerance. Int J Cardiol 168(5): 4667-4677, 2013.
43. Tian F, Zhou X, Wikstrom J, Karlsson H, Sjoland H, Gan LM, Boren J and Akyurek LM: Protein disulfide isomerase increases in myocardial endothelial cells in mice exposed to chronic hypoxia: a stimulatory role in angiogenesis. Am J Physiol Heart Circ Physiol 297(3): H1078-1086, 2009.